Redeye: BioInvent Q3 2023 - One Step Forward on the Road to Partnering with BI-1808
Redeye comments on the third quarter report of BioInvent. All projects are progressing. Importantly, BI-1808 is the second program, after BI-1206, to advance into phase II. The subcutaneous version of BI-1206 is being studied with results expected by H1 2024 in lymphoma.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/